NCT01163383 2026-04-13
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Children's Hospital of Philadelphia
Available
Clinical Trials
47 trialsNCT05028166 2026-03-27
Individual Patient Compassionate Use of Mirdametinib
SpringWorks Therapeutics, Inc.
Available
NCT07497984 2026-03-27
ITM11 Expanded Access Program
ITM Solucin GmbH
Available
NCT06404034 2026-03-04
Expanded Access to Gallium Maltolate (GaM)
Imaging Biometrics, LLC
No longer available
NCT03581240 2026-02-20
An Intermediate Expanded Use Trial of DFMO
Milton S. Hershey Medical Center
Available
NCT04566393 2026-01-28
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
xCures
Available
NCT07223606 2025-11-03
Fecal Microbiota Transplant for Neuroblastoma in a Single Patient
ProgenaBiome
No longer available
NCT05511714 2025-10-16
Expanded Access [11C] Methionine PET Imaging
St. Jude Children's Research Hospital
Available
NCT05974410 2025-10-02
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
AVM Biotechnology Inc
Available
NCT04802447 2025-09-16
EAP
Roswell Park Cancer Institute
No longer available
NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
NCT05064306 2025-08-01
131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults
Memorial Sloan Kettering Cancer Center
No longer available
NCT06872489 2025-07-23
Expanded Access Protocol for the Use of SL-28 in the Treatment of Advanced Solid Tumors
Second Life Therapeutics
Available
NCT01370330 2025-07-22
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
University of California, San Francisco
Available
NCT06743100 2025-04-02
18F-Floretyrosine Expanded Access Program
Telix Pharmaceuticals (Innovations) Pty Limited
Available
NCT06676891 2025-01-08
Expanded Access Program for GBM Subjects
Rznomics, Inc.
Available
NCT03649438 2024-12-11
131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma
University of Texas Southwestern Medical Center
No longer available
NCT05518838 2024-11-08
Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered
Oblato, Inc.
No longer available
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT04714086 2024-10-24
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
No longer available
NCT05936216 2024-10-01
TVI-Brain-1 in Expanded Access Patient
TVAX Biomedical
No longer available
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing
NCT05551013 2024-08-09
Treatment of Recurrent GBM With APG-157 Via Expanded Access
Aveta Biomics, Inc.
No longer available
NCT06439849 2024-07-16
TRIANGLE
Petrov, Andrey
No longer available
NCT03015844 2024-07-05
A Compassionate Use/Expanded Access Protocol Using 131I-MIBG Therapy for Patients With Refractory Neuroblastoma and Metastatic Pheochromocytoma
Northwell Health
Available
NCT04321694 2024-04-25
Expanded Access for KHK2455
Kyowa Kirin Co., Ltd.
No longer available
NCT05356312 2024-03-01
Glioblastoma and Individualized Therapies
Zentrum fur Humangenetik Tuebingen
Available
NCT01838187 2023-08-18
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma
Children's Hospital Medical Center, Cincinnati
No longer available
NCT01590680 2023-02-28
Expanded Access Protocol Using 131I-MIBG
Jubilant DraxImage Inc.
Available
NCT02431715 2023-02-21
18F-FDOPA PET in Neuroendocrine Tumours
British Columbia Cancer Agency
No longer available
NCT04599647 2022-06-29
EAP for the Treatment of Glioblastoma With PVSRIPO
Istari Oncology, Inc.
No longer available
NCT05392374 2022-05-26
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
Jazz Pharmaceuticals
No longer available
NCT02075177 2022-03-21
Expanded Access Study of Fenretinide Lym-X-Sorb Plus Ketoconazole in Neuroblastoma
South Plains Oncology Consortium
No longer available
NCT04289155 2022-03-17
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
No longer available
NCT03134131 2022-03-14
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Jazz Pharmaceuticals
No longer available
NCT01377532 2020-05-06
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma
University of California, San Francisco
Approved for marketing
NCT03259633 2020-05-01
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
AstraZeneca
Approved for marketing
NCT03424473 2020-02-25
Expanded Access Use of Tucatinib for HER2+ Metastatic Breast Cancer
Seagen Inc.
No longer available
NCT02589912 2019-12-06
Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Massachusetts Eye and Ear Infirmary
No longer available
NCT03460782 2019-11-08
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Center Trials & Treatment
No longer available
NCT03123952 2019-07-15
Expanded Access to ABT-414
AbbVie
No longer available
NCT02961491 2019-01-30
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma
Molecular Insight Pharmaceuticals, Inc.
Approved for marketing
NCT03311542 2018-01-10
Expanded Access for Pembrolizumab (MK-3475)
Center Trials & Treatment
No longer available
NCT03068650 2017-10-18
CDX-110
Celldex Therapeutics
No longer available
NCT02755987 2016-06-07
Expanded Access to ANG1005 for Individual Patients
Angiochem Inc
No longer available
NCT02146066 2016-02-26
DCVax-L EAP
Northwest Biotherapeutics
Available
NCT00730444 2009-11-09
Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma
GE Healthcare
Approved for marketing